Repligen Corporation with ticker code (RGEN) now have 13 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between 240 and 165 and has a mean target at $197.62. Given that the stocks previous close was at $165.50 this would imply there is now a potential upside of 19.4%. The 50 day MA is $165.62 and the 200 day moving average is $168.09. The total market capitalization for the company now stands at 9.08B. The current share price for the company is: 162.94 USD
The potential market cap would be $10,848,122,543 based on the market consensus.
The company has a dividend yield of 5.38%. Other points of data to note are a P/E ratio of 69.63, revenue per share of 13.12 and a 3.46% return on assets.
Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company’s bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.
